Detalhe da pesquisa
1.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 24(2): 202-210, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190302
2.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 714-23, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23054206
3.
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.
Commun Med (Lond)
; 3(1): 120, 2023 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37684373
4.
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
Clin Cancer Res
; 20(23): 5918-26, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261556
5.
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
Clin Cancer Res
; 18(17): 4820-9, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22767667
6.
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
J Clin Oncol
; 26(11): 1810-6, 2008 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18347007